Lalonde James Joseph has reported a stock option grant of 10,000 shares in Exozyme Inc., a biological products company. This move is significant as it demonstrates the company's strategy to align the interests of its executives with those of its shareholders.
Exozyme Inc. is incorporated in Nevada and operates in the biological products sector. The company, which has undergone a name change from Invizyne Technologies Inc. earlier this year, focuses on developing innovative solutions in life sciences. Its recent filings indicate a commitment to growth and personnel investment.
According to the filing dated October 19, 2026, Lalonde's stock option has an exercise price of $6.28 and will vest in quarterly installments over three years, starting December 31, 2026. The option is set to expire on October 1, 2033. The filing states, "The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 833 shares and a final installment of 837 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer."
This stock option grant may affect the company's ability to attract and retain key talent, particularly in a competitive industry like biological products. By providing such incentives, Exozyme Inc. aims to motivate its executives to drive the company's growth and innovation.
Details regarding future plans or additional filings were not available in the SEC filing.